Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Shared idiotypes expressed by human B-cell lymphomas.

R A Miller1, S Hart, M Samoszuk

  • 1IDEC Pharmaceuticals Corporation, Mountain View, Calif 94043.

The New England Journal of Medicine
|September 28, 1989
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Drug prevalence in Canadian driving population.

Traffic injury prevention·2025
Same author

A multi-centre retrospective study of Nocardia speciation and antimicrobial susceptibility in Queensland, Australia.

European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology·2023
Same author

Second surgery for progressive glioblastoma: a multi-centre questionnaire and cohort-based review of clinical decision-making and patient outcomes in current practice.

Journal of neuro-oncology·2021
Same author

Systematic rifampicin resistance errors with Xpert<sup>®</sup> MTB/RIF Ultra: implications for regulation of genotypic assays.

The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease·2020
Same author

Drug-resistant tuberculosis diagnosis since Xpert<sup>®</sup> MTB/RIF introduction in Papua New Guinea, 2012-2017.

Public health action·2019
Same author

Responding to Mycobacterium chimaera heater-cooler unit contamination: international and national intersectoral collaboration coordinated in the state of Queensland, Australia.

The Journal of hospital infection·2018

Researchers developed a panel of anti-idiotype antibodies for B-cell lymphoma. This approach identifies shared idiotypes across patient tumors, reducing the need for patient-specific antibody production.

Area of Science:

  • Immunology
  • Oncology
  • Biotechnology

Background:

  • B-cell lymphomas express unique surface immunoglobulin idiotype determinants.
  • Developing patient-specific anti-idiotype antibodies is labor-intensive.

Purpose of the Study:

  • To produce and analyze murine monoclonal antibodies against idiotypes from follicular small-cleaved-cell lymphoma.
  • To determine the feasibility of using a panel of anti-idiotype antibodies for B-cell lymphoma diagnosis and classification.

Main Methods:

  • Generated 199 monoclonal antibodies targeting idiotypes from 67 follicular small-cleaved-cell lymphoma patients.
  • Screened antibodies for reactivity against lymphoma cells from different patients.
  • Analyzed idiotype sharing frequency and patterns across B-cell lymphoma subtypes.

Related Experiment Videos

Main Results:

  • Twenty anti-idiotype antibodies reacted with lymphoma cells from multiple patients, indicating shared idiotypes.
  • Idiotype sharing frequency ranged from 0.6% to 6.2% among B-cell lymphoma tumors.
  • A panel of 20 antibodies identified shared idiotypes in 33% of 150 B-cell lymphomas, including 27% of follicular small-cleaved-cell lymphomas.

Conclusions:

  • A panel of anti-idiotype antibodies can detect shared idiotypes in B-cell lymphomas.
  • This strategy obviates the need for individual patient-specific anti-idiotype antibody production.
  • Shared idiotypes can be identified across various lymphoma subtypes, aiding in classification.